Regenxbio Inc is a pioneering biotechnology firm focused on developing gene therapies for genetic defects. Leveraging its NAV Technology Platform, the company is advancing a diverse pipeline of treatments targeting serious conditions like wet age-related macular degeneration, diabetic retinopathy, Duchenne muscular dystrophy, and various mucopolysaccharidoses. With a commitment to innovation, Regenxbio also collaborates with industry partners, including a significant agreement with AbbVie for international development. Founded in 2008 and based in Rockville, Maryland, Regenxbio is at the forefront of gene therapy research and development.
Among the Wall Street firms investors often pay closest attention to, Goldman Sachs (NYSE:GS | GS Price Prediction) has to be atop the list. The investment banking giant has accumulated some of…
